Market Overview:
The global CARD9 deficiency treatment market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing incidence of fungal infections, rising awareness about CARD9 deficiency treatment, and technological advancements in the field of CARD9 deficiency treatment. However, factors such as high cost of diagnosis and treatment and lack of reimbursement policies are restraining the growth of this market. The global CARD9 deficiency treatment market is segmented on the basis of type, application, and region. On the basis of type, it is divided into systemic antifungal infections and superficial antifungal infections. Systemic antifungal infections are further classified into invasive candidiasis (IC), aspergillosis (A), mucormycosis (M), zygomycosis (Z), fusariosis (F), blastomycosis (Bt) , histoplasmosis(Hs) , chromoblastomycoses(Cb). Superficial fungal infection includes dermatophytoses or ringworm infection caused by fungi that live on dead tissue cells in hair shafts, skin scales or nails., tinea corporis which affects body trunk excluding scalp; tinea cruris which affects groin area; tinea pedis which affects feet; onychomycoses which affect nails.
Product Definition:
CARD9 deficiency is a rare genetic disorder that results in the inability to fight against infection. Treatment consists of antibiotics to treat any existing infections and prevent new ones, as well as other treatments depending on the specific symptoms present. CARD9 deficiency is important because it can lead to serious health problems if not treated.
Systemic Antifungal Infections:
Systemic antifungal infections are widespread fungal and yeast infections that affect the skin, hair, mouth, and vagina. The most common types of systemic fungal infection include athlete's foot, ringworm (tinea corporis), jock itch (tinea cruris), and toenail fungus (onychomycosis). Systemic yeast infection includes thrush or glossitis.
Superficial Antifungal Infections:
Superficial fungal infections (SFI) are common in patients with chronic diseases such as diabetes, cancer and other immunosuppressive conditions. The incidence of SFI is high in the geriatric population and individuals suffering from HIV/AIDS. In addition, the use of corticosteroids and antibiotics may increase susceptibility to superficial fungal infections.
Application Insights:
The other application segment includes environmental applications, food and beverages processing, textiles and leather processing. The others segment dominated the global market in terms of revenue in 2017. This is due to the high prevalence of fungal infections caused by Aspergillus species, Fusarium species and Alternaria spp., which are responsible for widespread hospital admissions every year. In addition, this fungus also affects a large number of individuals across the globe owing to its ability to colonize almost any surface including walls, furniture surfaces as well as household items such as carpets and curtains. Therefore, it has been estimated that around 1 in 5 people develop some form of infection due to this fungus annually worldwide.
CARD9 deficiency treatment finds extensive usage across hospitals for systemic fungal infections (SFIs) caused by Candida spp., Aspergillus fumigatus or both fungi together known as Mixed Infection (MI).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high treatment cost and availability of insurance coverage for treating systemic fungal infections. In addition, increasing prevalence of these conditions is also expected to boost demand for this therapy in North America over the forecast period. For instance, as per a recent study published by National Institute of Health (NIH), around 8 million people are affected by ringworm across U.S., which is an increase from 6 million reported in 2012 and 2013 respectively.
Asia Pacific region is anticipated to witness lucrative growth over the forecast period owing to rising disposable income leading to increased adoption of healthcare facilities among individuals as well as improving infrastructure facilitating easy access by patients.
Growth Factors:
- CARD9 Deficiency Treatment market is growing due to increasing incidence of CARD9 Deficiency.
- The CARD9 Deficiency Treatment market is growing due to the increasing number of research and development activities for new drugs and therapies for the treatment of cardiomyopathy.
- The CARD9 Deficiency Treatment market is growing due to the rising awareness about this disorder among people, which is resulting in earlier diagnosis and treatment interventions.
- The CARD9 Deficiency Treatment market growth can be attributed to technological advancements that are helping in early diagnosis and better management of this disorder .
Scope Of The Report
Report Attributes
Report Details
Report Title
CARD9 Deficiency Treatment Market Research Report
By Type
Systemic Antifungal Infections, Superficial Antifungal Infections
By Application
Hospital, Clinic, Pharmacy, Other
By Companies
Astellas Pharma, Basilea Pharmaceutical, Tecan Group, Bausch Health, Beckman Coulter, Agilent Technologies, Merck, Abbott Laboratories, Sanofi, Pfizer, Novartis International
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
158
Number of Tables & Figures
111
Customization Available
Yes, the report can be customized as per your need.
Global CARD9 Deficiency Treatment Market Report Segments:
The global CARD9 Deficiency Treatment market is segmented on the basis of:
Types
Systemic Antifungal Infections, Superficial Antifungal Infections
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Pharmacy, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Astellas Pharma
- Basilea Pharmaceutical
- Tecan Group
- Bausch Health
- Beckman Coulter
- Agilent Technologies
- Merck
- Abbott Laboratories
- Sanofi
- Pfizer
- Novartis International
Highlights of The CARD9 Deficiency Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Systemic Antifungal Infections
- Superficial Antifungal Infections
- By Application:
- Hospital
- Clinic
- Pharmacy
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the CARD9 Deficiency Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
CARD9 deficiency is a rare genetic disorder that results in the inability to produce enough cardiotrophin-1, a hormone that helps regulate heart function. CARD9 deficiency can cause serious health problems, including heart failure and sudden death. Treatment for CARD9 deficiency typically includes medications and surgery to improve heart function.
Some of the key players operating in the card9 deficiency treatment market are Astellas Pharma, Basilea Pharmaceutical, Tecan Group, Bausch Health, Beckman Coulter, Agilent Technologies, Merck, Abbott Laboratories, Sanofi, Pfizer, Novartis International.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 CARD9 Deficiency Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 CARD9 Deficiency Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 CARD9 Deficiency Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the CARD9 Deficiency Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global CARD9 Deficiency Treatment Market Size & Forecast, 2018-2028
4.5.1 CARD9 Deficiency Treatment Market Size and Y-o-Y Growth
4.5.2 CARD9 Deficiency Treatment Market Absolute $ Opportunity
Chapter 5 Global CARD9 Deficiency Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 CARD9 Deficiency Treatment Market Size Forecast by Type
5.2.1 Systemic Antifungal Infections
5.2.2 Superficial Antifungal Infections
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global CARD9 Deficiency Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 CARD9 Deficiency Treatment Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Pharmacy
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global CARD9 Deficiency Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 CARD9 Deficiency Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America CARD9 Deficiency Treatment Analysis and Forecast
9.1 Introduction
9.2 North America CARD9 Deficiency Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America CARD9 Deficiency Treatment Market Size Forecast by Type
9.6.1 Systemic Antifungal Infections
9.6.2 Superficial Antifungal Infections
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America CARD9 Deficiency Treatment Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Pharmacy
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe CARD9 Deficiency Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe CARD9 Deficiency Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe CARD9 Deficiency Treatment Market Size Forecast by Type
10.6.1 Systemic Antifungal Infections
10.6.2 Superficial Antifungal Infections
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe CARD9 Deficiency Treatment Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Pharmacy
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific CARD9 Deficiency Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific CARD9 Deficiency Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific CARD9 Deficiency Treatment Market Size Forecast by Type
11.6.1 Systemic Antifungal Infections
11.6.2 Superficial Antifungal Infections
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific CARD9 Deficiency Treatment Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Pharmacy
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America CARD9 Deficiency Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America CARD9 Deficiency Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America CARD9 Deficiency Treatment Market Size Forecast by Type
12.6.1 Systemic Antifungal Infections
12.6.2 Superficial Antifungal Infections
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America CARD9 Deficiency Treatment Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Pharmacy
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) CARD9 Deficiency Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) CARD9 Deficiency Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) CARD9 Deficiency Treatment Market Size Forecast by Type
13.6.1 Systemic Antifungal Infections
13.6.2 Superficial Antifungal Infections
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) CARD9 Deficiency Treatment Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Pharmacy
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 CARD9 Deficiency Treatment Market: Competitive Dashboard
14.2 Global CARD9 Deficiency Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Astellas Pharma
14.3.2 Basilea Pharmaceutical
14.3.3 Tecan Group
14.3.4 Bausch Health
14.3.5 Beckman Coulter
14.3.6 Agilent Technologies
14.3.7 Merck
14.3.8 Abbott Laboratories
14.3.9 Sanofi
14.3.10 Pfizer
14.3.11 Novartis International
